SARASOTA, Fla., Nov. 02, 2018 (GLOBE NEWSWIRE) — via OTC PR WIRE — PRESS RELEASE — Kali, Inc. (USOTC: KALY) has published the online presentation included here below to detail the strategy behind the recently announced plans with Puration, Inc. (USOTC: PURA) and Nouveau Life Pharmaceuticals, Inc. (USOTC: NOUV) to form a joint venture (JV) company to develop cannabis pharmaceutical products. The cannabis pharmaceutical market is anticipated to reach a value of $50 billion by 2029.
KALY has partnered with PURA and NOUV to form U.S. Cannabis Health, a JV company formed for the development of cannabis pharmaceutical and wellness products. The cannabis pharmaceuticals market is forecasted to reach a $50 billion sales by 2029.
Big Pharma names have already entered the space with Pfizer and Merck actually owning cannabis IP in addition the more entrepreneurial companies such as GW Pharmaceuticals that have made recent notable splashes in the market place.
What each JV Partner Brings To the Party
Kali recently announced a letter of intent to acquire NCM Biotech, the developer and owner of a patented cannabis extraction process – U.S. Patent No. 9,199,960 entitled “METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.” Kali and NCM anticipate closing the acquisition this month. NCM’s proprietary extracts have already been involved in a number of medical trials. In that regard, NCM brings a medical advisory team that includes John N. Gaitanis, MD., Director of Child Neurology at Tufts Medical Center/Floating Hospital for Children; Lloyd R. Saberski, M.D., Associate Professor of Anesthesiology and Chronic Pain Management, Yale University, and John McMichael, Ph.D., President & CEO Beech Tree Labs.
PURA has previously licensed the NCM Biotech patent for use in specific commercial applications. PURA brings its commercial experience to the planned pharmaceutical JV. PURA also brings its network and experience in the Sports Nutrition market..
Nouveau has recently acquired a cannabis cultivation operation from Puration. In the JV, Nouveau would be tasked with developing a proprietary pharmaceutical grade hemp cultivar. The acquired cannabis cultivation has already initiated efforts toward developing a proprietary, pharmaceutical grade hemp cultivar.
The JV partners have already engaged in discussions with a university and separately, a pharmaceutical firm, about forming a partnership for the development of specific cannabis therapeutic treatments. The JV will expand its reach beyond these first two potential partners until it strikes the appropriate research partnerships.
No research takes place without adequate funding. Each JV partner is contributing and at the same time working together to secure third party financing. At this time the company has two financing strategies. One is centered around private financing and one around an independent listing of the JV. The ultimate path will depend on the nature of the investor.